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The concept of immune surveillance against cancer 
was initially formulated with thymus-dependent immu­
nity as a central and requisite effector mechanism. How­
ever, a substantial amount of evidence has accumulated 
to indicate that T cell-mediated immunity is mainly 
important for protection against tumors induced by on­
cogenic viruses and not for many other types of sponta­
neous or chemical carcinogen-induced tumors. It now 
appears likely that various components of the natural 
immune system also play major roles in immune sur­
veillance. These include natural killer (NK) cells and 
macrophages. The existing evidence for the roles of 
these effector cells is discussed. 
The general role of the immune system in preventing or 
limiting tumor growth has been proposed by many investiga­
tors. The central concept, which has come to be known as the 
immune surveillance hypothesis, postulates that the immune 
system plays a central role in resistance against the develop­
ment of detectable tumors. The first known suggestion along 
these lines came from Paul Ehrlich in 1909 [1]. The modern 
formulation of the hypothesis originated from Burnet [2] and 
Thomas [3]. When information about thymus-dependent im­
munity became known, and particularly when T cells were 
found to play a central role in homograft rejection, the immune 
surveillance hypothesis was modified by Burnet to stress the 
key role of this effector mechanism in antitumor resistance 
[4]. 
Since these original formulations, the immune surveillance 
hypothesis has generated many experimental studies and much 
discussion and controversy. One of the reasons for the contro­
versy is that the concept leads to a series of predictions, and 
most available evidence relates to tests of one or more of the 
following predictions: (1) tumor cells have transplantation-type 
antigens, (2) resistance against tumors is T cell-dependent and 
analogous to the homograft reaction, (3) there is a close evo­
lutionary link between malignancy and the development of an 
immune system with a capability for rejection of tumors, (4) 
immune depression is associated with, and must precede, de­
velopment of detectable tumors, and (5) a requisite action of 
carcinogens and/or tumor promoters might be immunosuppres­
sion. 
The main support for the immune surveillance hypothesis 
has come from evidence related to prediction 4, since naturally 
occurring or induced immunodepression has been associated 
with a higher incidence of some types of tumors. In experimen­
tal tumors, this has been most clearly demonstrated with those 
induced by oncogenic viruses. Neonatal thymectomy and other 
forms of immune suppression have been shown to lead to 
increased susceptibility to polyoma virus-induced tumors in 
mice [5] and Marek's disease in chickens [6]. There is also 
considerable clinical evidence that immune deficiency diseases 
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are associated with a much higher incidence of lymphomas and 
leukemias [7]. Allograft recipients receiving immunosuppres­
sive agents, mainly prednisone and azathioprine, have also been 
found to have an increased incidence (approximately 100-fold 
increase) of tumors [8]. Patients with cancer, arthritis, or other 
diseases who received chemotherapeutic (mainly alkylating) 
agents have been subsequently found to develop a relatively 
high frequency of primary malignancies, mainly leukemias and 
lymphomas [9]. The recent observations of a remarkably high 
incidence of Kaposi's sarcoma in young adults with the acquired 
immune deficiency syndrome are yet another indication of the 
association of malignancy with immunodepression. 
Although such data have lent considerable support to the 
immune surveillance hypothesis, several major problems or 
limitations of the original hypothesis were noted. First, the 
majority of human tumors associated with immunodepression 
have been leukemias and lymphomas, rather than a complete 
array of the common types of malignancy. Second, there has 
been a lack of a consistent association between immunodepres­
sion and tumors [10]. Third, neonatally thymectomized mice 
have been found to have a decreased incidence of mammary 
tumors [11], and nude and euthymic mice have similar inci­
dences of spontaneous and carcinogen-induced tumors [10]. 
Fourth, most spontaneous tumors of experimental animals lack 
detectable tumor-associated transplantation antigens [12]. Fi­
nally, there has also appeared to be an evolutionary dissociation 
between the development of tumors and the appearance of a 
sophisticated immune system and T cells [13]. 
These hypotheses have led to the suggestion [14] that im­
mune surveillance may be operative only against tumors in­
duced by oncogenic viruses, which have strong transplantation 
antigens and for which immune T cells have been shown to be 
important in resistance. Other investigators have reacted to 
such information in a more pessimistic way. For example, 
Nossal [15] suggested that immune surveillance and tumor 
immunology in general were moribund if not terminally ill. The 
major exceptions to the central role of immune T cells in 
resistance to tumor growth have even led to a countertheory of 
immunostimulation [16], suggesting that the immune system 
may have mainly enhancing effects on tumor induction and 
growth. 
A more likely explanation for many of the discordant results 
is that a variety of effector mechanisms may be involved in 
host resistance. In the last few years it has become apparent 
that natural immuniity, as well as specifically induced immune 
responses, may contribute to host defenses. When T cell­
mediated immunity is viewed as only one of a series of possible 
host defense mechanisms, the evidence summarized above need 
not be viewed in such a negative light. Target cell structures 
other than tumor-associated transplantation antigens might be 
involved in recognition by other types of effector cells, and in 
T cell-deficient individuals, natural immunity might still be 
functional and capable of resisting tumor growth. 
POSSIBLE EFFECTORS OF IMMUNE 
SURVEILLANCE 
Possible Role of T Cells in Immune Surveillance 
As indicated above, there is substantial evidence that thy­
mus-dependent immune responses play a central role in resist-
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ance to tumors induced by oncogenic viruses. However, the 
absence of the thymus has not been associated with increased 
susceptibility to other types of tumors, suggesting a limited role 
for T-cell immunity in immune surveillance. Further, the ina­
bility to detect tumor-associated transplantation antigens on 
most spontaneous rodent tumors argues against a major in­
volvement of specific immune responses. 
What then are the likely alternatives to T cell-mediated 
immunity in antitumor resistance and immune surveillance? 
There are a variety of possibilities, including macrophages, 
natural killer (NK) cells, natural cytotoxic (NC) cells and other 
components of the natural immune system, granulocytes, and 
antibody-dependent cellular cytotoxicity (ADCC) with natural 
or induced antibodies. Based on these possibilities, one may 
formulate an updated immune surveillance hypothesis: Trans­
formed cells express surface antigens or other structures that 
can be recognized by one or more components of the immune 
system. One or more components of the natural and/or induced 
immunologic effector mechanisms can eliminate the trans­
formed cells or impede the progression and spread of tumors. 
This broader hypothesis leads to a somewhat different set of 
predictions: First, tumor cells have surface structures recog­
nized by one or more effectors. Second, tumor cells will be 
susceptible to lysis or growth inhibition by one or more effector 
mechanisms. Third, one or more of the relevant effector cells 
should be able to enter the site of tumor growth. Fourth, 
augmentation of relevant effector mechanism(s) will decrease 
the incidence of tumors or of metastases. Fifth, depression of 
relevant effector mechanism(s), either by carcinogen or by 
immunosuppressive treatment, will increase the incidence of 
tumors or metastases. Finally, restoration of depressed effector 
activity will decrease the incidence of tumors or metastases. 
Possible Role of Macrophages in Immune Surveillance 
Many investigators have suggested that macrophages might 
play an important role in antitumor defenses and might be 
primarily responsible for immune surveillance against tumors 
[17,18], and this possibility is supported by several lines of 
evidence: First, there is abundant evidence that macrophages 
can accumulate in considerable numbers in a variety of trans­
plantable tumors [19] and in many primary tumors [20]. Sec­
ond, macrophages have natural [21] as well as the rapidly 
activatable ability to lyse or inhibit the growth in vitro of a 
wide variety of transformed cells. Third, several treatments 
that can depress the function of macrophages (e.g., silica or 
carrageenan) have been associated with an increased incidence 
of tumors and metastases [22]. Fourth, adoptive transfer of in 
vitro or in vivo activated macrophages was shown to inhibit 
the metastatic spread of some tumor cell lines [23,24]. Fifth, 
some carcinogens (e.g., methylcholanthrene and acetylamino­
fluorene) have been shown to depress reticuloendothelial func­
tion [25]. Finally, stimulation of macrophage function by var­
ious immunomodulators has been associated with decreased 
tumor growth or a decreased incidence of tumors [22]. 
It should be noted that there are some major limitations to 
such evidence: First, there is remarkably little evidence that 
macrophages have cytotoxic activity against primary, freshly 
harvested tumor cells, as opposed to established tumor cell 
lines. Second, silica and carrageenan, and virtually all the other 
depressive treatments that have been used, may not be entirely 
selective in their effects. In fact, they may cause increases in 
some functions, particularly suppressor activity, by macro­
phages or other cells [26]. Further, the effects of such treat­
ments on tumor growth are not always in the same direction, 
even with the same tumor. For example, Mantovani et al [27] 
found that treatment of mice with silica or carrageenan in­
creased the incidence of pulmonary metastases but inhibited 
the growth of the primary tumors. Third, the carcinogens shown 
to depress reticuloendothelial function may also have affected 
a variety of effector mechanisms, and other carcinogens have 
Vol. 83, No.1 Supplement 
had no detectable effects on macrophage or reticuloendothelial 
function [28]. 
Possible Role of NK Cells in Immune Surveillance 
Natural killer (NK) cells have come to be recognized as a 
discrete subpopulation of lymphoid cells with spontaneous cy­
totoxic reactivity against a variety of tumor cell lines and 
primary tumor cells, as well as against virus-infected cells and 
some normal cells (for a comprehensive compendium of recent 
information on the charactertistics of NK cells, see [29]). NK 
cells are readily distinguishable by their cell surface phenotype 
and by their pattern of specificity (particularly the lack of 
major histocompatibility complex restriction to their activity) 
from classical cytotoxic T cells. They are also nonphagocytic 
and generally nonadherent and thus distinguished from typical 
macrophages, monocytes, and granulocytes. It has recently 
become clear that a small, morphologically identifiable subpop­
ulation of lymphoid cells, termed large granular lymphocytes 
(LGL), accounts for virtually all NK activity in humans and 
rats, and this close association also seems to pertain to mouse 
NK cells. LGL, which represent 5-10% of the mononuclear 
cells in the peripheral blood or spleen, can be enriched to as 
much as 90% purity, primarily by centrifugation on discontin­
uous gradients of Percoll. The ability to prepare highly enriched 
populations of NK cells has allowed extensive characterization 
of the cell surface phenotype of NK cells. In general, they have 
been shown to express some markers that have been associated 
with T cells or with macrophages or granulocytes. 
There is substantial evidence for an important role of NK 
cells in in vivo resistance against established cell lines of 
tumors, particularly those which show susceptibility to in vitro 
cytolysis by NK cells (summarized in [30]). In addition, there 
are several types of evidence that conform to the predictions of 
the immune surveillance hypothesis: First, NK cells have been 
shown to be able to accumulate at sites of inflammation [31] 
and in small primary as well as transplanted tumors [32]. 
Second, NK cells have a natural and also rapidly act iva table 
ability to lyse a variety of primary autochthonous tumors [33, 
34]. Third, there is considerable evidence for the ability of NK 
cells to eliminate metastatic tumor cells and thereby resist 
tumor spread. Fourth, an increased tumor incidence (primarily 
lymphomas) has been found in individuals with depressed NK 
activity (beige mice [35], patients with Chediak-Higashi syn­
drome [36], and immunosuppressed transplant recipients [8]). 
Some carcinogens (urethane, "1- or x-irradiation, and dimethyl­
benzanthracene) have been shown to cause early, profound 
depression of NK activity [37-40]. 
The most convincing data relate to the important role of NK 
cells in host resistance against metastases. The observation 
that NK cells appear to be mainly responsible for the rapid 
elimination of intravenously inoculated tumor cells provided 
the initial indication that this effector mechanism might pro­
vide a very effective control of hematogenous spread of tumors 
[41]. Experimental support for this possibility first came from 
the finding that cells from the lung metastases of a transplant­
able tumor in mice were more resistant to NK activity than 
locally growing tumor cells [42]. An important role of NK cells 
in resistance against metastatic growth of transplantable tu­
mors has been further supported by observations that suppres­
sion or augmentation of NK activity of mice was associated 
with parallel alterations in resistance to artificial metastases 
produced by intravenous inoculation of tumor cells [43,44]. The 
patterns of results obtained in these studies suggested that NK 
cells may primarily influence metastatic spread of tumors by 
acting during the phase of hematogenous dissemination, pre­
sumably by their ability to rapidly eliminate the tumor cells 
from the circulation of capillary beds. As further confirmation 
of the association between depressed NK activity and increased 
metastases, Barlozzari et al (manuscript in preparation) have 
shown that selective restoration of NK activity in rats by 
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adoptive transfer of highly purified large granular lymphocytes 
was accompanied by increased resistance to pulmonary metas­
tases. Similarly, Warner and Dennert [45] showed that adoptive 
transfer of a clone of cultured lymphoid cells with NK-like 
activity protected against development of pulmonary or liver 
metastases. 
Direct evidence for a possible role of NK cells in immune 
surveillance is quite limited and relates mainly to two models 
of carcinogenesis: First, there are several indications for a role 
of NK cells in protection against urethane-induced lung tumors 
in mice. This carcinogen produces lung tumors in only some 
strains of mice and was shown to cause transient and marked 
depression of NK activity in a susceptible strain [37] but not 
in resistant strains [46]. However, it is clear that genetically 
determined susceptibility to depression of NK activity by ure­
thane is only one of the factors determining the strain distri­
bution. C57BL/6 beige mice, with deficient NK activity, as well 
as normal C57BL/6 mice, were found to be highly resistant to 
urethane-induced lung tumors [47]. The resistance to lung 
carcinogenesis, even in the NK-deficient strain, is probably 
attributable to the known genetic resistance of the lung tissues 
of C57BL mice to transformation by urethane [48]. In further 
studies in A/J mice, which are highly susceptible to induction 
of lung tumors by urethane, a further reduction in NK activity 
by treatment with cyclophosphamide led to a significantly 
higher tumor incidence [47]. Conversely, adoptive transfer of 
normal spleen or bone marrow cells, which led to reconstitution 
of NK activity, also caused a significant inhibition in the 
subsequent incidence of lung tumors. In contrast, spleen cells 
from urethane-treated donors, which had low NK activity and 
were unable to restore NK activity in the recipients, had no 
significant ability to transfer resistance to development of lung 
tumors [47]. 
The other carcinogenesis system that has received consider­
able attention is the induction of thymic lymphomas by mul­
tiple low doses of -y-irradiation of C57BL/6 mice. Development 
of tumors in this system appears to be dependent on a complex 
series of factors, and it has been difficult to demonstrate a clear 
contribution of NK cells to the overall process of leukemo­
genesis [56]. However, NK cells did appear to be involved in 
protection against the transplantation of preleukemic bone 
marrow cells from donors that received fractionated doses of 
-y-irradiation. Recipients of the preleukemic bone marrow that 
were irradiated with 400 R were susceptible to leukemia and in 
parallel were found to have depressed NK activity. Whereas 
un irradiated C57BL/6 recipients were resistant, un irradiated 
C57BL/6 beige recipients were found to be susceptible to in­
duction of leukemia by the transferred bone marrow cells. As 
further evidence for the possible role of NK cells in this 
transplantation system, spleen cells of nude mice, which have 
high NK activity, protected against tbe transfer of leukemia, 
whereas spleen cells from mice with low NK activity did not 
protect. Further positive evidence for a role of NK cells in 
resistance against leukemogenesis has come from the studies 
of Warner and Dennert [45]. They found that adoptive transfer 
of cloned cells with NK-like activity, during a 4-week period 
after the last dose of fractionated -y-irradiation, conferred sub­
stantial protection against the development of leukemia. De­
spite such suggestive positive evidence for a role of NK cells, a 
series [56] of other experiments has indicated that non-NK­
related factors seemed to have a more important influence on 
the incidence of leukemia than did the levels of NK activity. 
Possible Role of NC Cells in Immune Surveillance 
As reviewed by Stutman et al [49], natural cytotoxic (NC) 
cells are another type of natural effector cell in mice that may 
be related to NK cells but lack some of the markers associated 
with NK cells and differ in some functional characteristics. 
Although some evidence has been obtained for an in vivo role 
of NC cells in resistance to tumor growth, to date little direct 
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evidence has been accumulated to support a role of NC cells in 
immune surveillance. 
Potentially Important Collaborations 
Between Different Effector Mechanisms 
It is important to note that more than one effector mecha­
nism may be involved in protection against development of a 
particular type of tumor. In addition to possible separate con­
tributions by two or more effector mechanisms, in many in­
stances the activity of a particular effector mechanism may be 
dependent on the activation or other form of collaboration from 
another component of the immune system. The best known 
example of such a collaboration is antibody-dependent cellular 
cytotoxicity (ADCC), in which natural or induced antibodies 
cooperate with effector cells. In addition to the well-known 
cytokine production by macrophages and by T cells, NK cells 
have been shown [50-53] to secrete a variety of cytokines 
(interferons, IL-l, IL-2, CSF, BCGF), and this function might 
contribute to the role of NK cells in resistance to tumors. It is 
also of note that lymphotoxin has been shown to have some 
anticarcinogenic activities in vitro and possibly also in vivo 
[54], and lymphotoxin-treated tumor cells had increased sus­
ceptibility to lysis by NK cells [55]. 
Another aspect to consider with regard to the possible in­
volvement of multiple effector cells is the possibility of sequen­
tial contributions by natural effeetor cells and immune T cells. 
Because of their spontaneous levels of reactivity and/or their 
ability to be rapidly activated, NK cells and macrophages might 
be viewed as a first line of defense against small numbers of 
transformed cells. If these natural effector cells are not com­
pletely effective in eliminating the tumor cells, immune T-cell 
reactivity might be induced and be responsible for the subse­
quent elimination of tumor cells. 
CONCLUSIONS 
In the context of the updated, broad formulation of the 
hypothesis, immune surveillance does appear to exist, at least 
for certain types of experimental and human tumors. This 
conclusion is based primarily on the considerable evidence that 
various forms of immunodepression have been associated with 
an increased incidence of tumors. A major challenge to tumor 
immunologists is to determine the possible effector mecha­
nism(s) involved in immune surveillance. This task will un­
doubtedly continue to be quite difficult, despite further studies 
along the lines outlined above. One problem is that most 
augmenting and suppressive treatments are not entirely selec­
tive for one effector mechanism. Furthermore, the lack of effect 
of a selective treatment on tumor incidence might be attribut­
able to compensatory protection from an alternative effector 
mechanism. Conversely, a positive effect of a selective suppres­
sive treatment on tumor incidence might only reflect coopera­
tive involvement of that effector mechanism, with a different 
mechanism actually being the effector of resistance. 
With such limitations in mind, what conclusions can be 
drawn from the available evidence as to the effector mecha­
nisms responsible for immune surveillance? First, a critical role 
for T cells appears limited to tumors with strong tumor-asso­
ciated transplantation antigens, particularly virus-induced tu­
mors. Second, NK cells appear to contribute to antitumor 
resistance, especially against metastases; however, the available 
data are limited to very few carcinogenesis systems. Third, 
insufficient data are available to draw satisfactory conclusions 
regarding the extent of involvement of other effector mecha­
nisms. 
With regard to the potential of immunomodulation for pro­
phylaxis or therapy of cancer, the questions of the overall 
efficacy of immune surveillance, or of the most relevant effector 
mechanisms in such resistance, are of secondary importance. 
Although natural host defenses may be inadequate to protect 
against tumor growth because of insufficiently low levels of 
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reactivity, augmentation of one or more effector mechanisms 
may inhibit and even abrogate malignant development. More 
studies focused on this important, practical issue are required. 
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